U.S. patent application number 12/639670 was filed with the patent office on 2010-04-15 for isoquinoline compounds.
This patent application is currently assigned to AERIE PHARMACEUTICALS, INC.. Invention is credited to Mitchell A. deLong, Allen E. Eckhardt, Brian H. Heasley, Christine Hudson, Clare Louise Murray, Byappanahally N. Narasinga Rao, Robert H. Oakley, Paresma R. Patel, Michael Peel, Thomas E. Richardson, Marcos L. Sznaidman, Jeffrey D. Yingling.
Application Number | 20100093790 12/639670 |
Document ID | / |
Family ID | 37157363 |
Filed Date | 2010-04-15 |
United States Patent
Application |
20100093790 |
Kind Code |
A1 |
deLong; Mitchell A. ; et
al. |
April 15, 2010 |
ISOQUINOLINE COMPOUNDS
Abstract
Isoquinoline compounds with G are provided that influence,
inhibit or reduce the action of a G-protein receptor kinase.
Pharmaceutical compositions including therapeutically effective
amounts of the isoquinoline compounds and pharmaceutically
acceptable carriers are also provided. Various methods using the
compounds and/or compositions to affect disease states or
conditions such as cancer, osteoporosis and glaucoma are also
provided.
Inventors: |
deLong; Mitchell A.;
(Raleigh, NC) ; Sznaidman; Marcos L.; (Durham,
NC) ; Oakley; Robert H.; (Durham, NC) ;
Eckhardt; Allen E.; (Durham, NC) ; Hudson;
Christine; (Durham, NC) ; Yingling; Jeffrey D.;
(Apex, NC) ; Peel; Michael; (Chapel Hill, NC)
; Richardson; Thomas E.; (Durham, NC) ; Murray;
Clare Louise; (Chapel Hill, NC) ; Narasinga Rao;
Byappanahally N.; (Chapel Hill, NC) ; Heasley; Brian
H.; (Wake Forest, NC) ; Patel; Paresma R.;
(San Diego, CA) |
Correspondence
Address: |
MICHAEL BEST & FRIEDRICH LLP
100 E WISCONSIN AVENUE, Suite 3300
MILWAUKEE
WI
53202
US
|
Assignee: |
AERIE PHARMACEUTICALS, INC.
Research Triangle Park
NC
|
Family ID: |
37157363 |
Appl. No.: |
12/639670 |
Filed: |
December 16, 2009 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12274887 |
Nov 20, 2008 |
|
|
|
12639670 |
|
|
|
|
11485172 |
Jul 11, 2006 |
7470787 |
|
|
12274887 |
|
|
|
|
60698165 |
Jul 11, 2005 |
|
|
|
Current U.S.
Class: |
514/310 ;
435/375; 546/143 |
Current CPC
Class: |
C07D 217/02 20130101;
A61P 17/00 20180101; A61P 27/06 20180101; A61P 13/00 20180101; A61P
19/08 20180101; A61P 9/00 20180101; A61P 9/12 20180101; A61P 19/00
20180101; A61P 37/08 20180101; A61P 15/08 20180101; A61P 13/10
20180101; A61P 1/16 20180101; A61P 1/18 20180101; A61P 35/00
20180101; A61P 3/04 20180101; A61P 9/10 20180101; A61P 1/00
20180101; A61P 11/02 20180101; A61P 27/02 20180101; A61P 13/12
20180101 |
Class at
Publication: |
514/310 ;
546/143; 435/375 |
International
Class: |
A61K 31/472 20060101
A61K031/472; C07D 217/02 20060101 C07D217/02; C07D 401/12 20060101
C07D401/12; C12N 5/00 20060101 C12N005/00; A61K 31/4725 20060101
A61K031/4725; A61P 27/02 20060101 A61P027/02; A61P 19/00 20060101
A61P019/00; A61P 9/00 20060101 A61P009/00; A61P 13/12 20060101
A61P013/12 |
Claims
1. A compound according to Formula (I): ##STR00045## wherein A is a
substituted or unsubstituted isoquinoline radical wherein the
isoquinoline radical may be mono- or disubstituted with halogen,
cyano, nitro, or C.sub.1-C.sub.4 alkyl; R.sup.1, R.sup.2, R.sup.3,
R.sup.4, and R.sup.5 are, independently, hydrogen, halogen;
C.sub.1-C.sub.8 alkyl, alkoxy, phenoxy, --OR.sup.7, amino, nitro,
cyano, aryl, C.sub.1-C.sub.4 alkylaryl, heteroaryl, C.sub.1-C.sub.4
alkyl heteroaryl, carbonylamino, thioalkyl, sulfonyl,
sulfonylamino, acyl, or carboxyl; R.sup.7 is C.sub.1-C.sub.4 alkyl,
aryl, heteroaryl, C.sub.1-C.sub.4 alkyl aryl, or C.sub.1-C.sub.4
alkyl heteroaryl; X is O; and R.sup.6 is CH.sub.2 or
CH(C.sub.1-C.sub.4 alkyl).
2. A compound according to claim 1, wherein R.sup.1, R.sup.2,
R.sup.3, R.sup.4, and R.sup.5 are not phenoxy.
3. A compound according to claim 1, wherein A is an unsubstituted
isoquinoline radical and R.sup.1, R.sup.3, and R.sup.5 are
hydrogen.
4. A compound according to claim 1, wherein R.sup.1, R.sup.2,
R.sup.3, and R.sup.5 are hydrogen and R.sup.4 is --O--R.sup.7.
5. A compound according to claim 1, wherein R.sup.4 is
carbonylamino, sulfylamino, acyl, or carboxyl.
6. A compound according to claim 1, wherein R.sup.1, R.sup.2, and
R.sup.5 are H and one of R.sup.3 and R.sup.4 is carbonylamino,
sulfylamino, acyl, or carboxyl.
7. A compound according to Formula (II): ##STR00046## wherein
R.sup.1', R.sup.2', R.sup.3', R.sup.4', and R.sup.5' are,
independently, hydrogen, halogen, unsubstituted C.sub.1-C.sub.4
alkyl, amino, nitro, cyano, carbonylamino, alkoxy, sulfonylamino,
carboxyl, acyl, or thioalkyl; R.sup.7' is C.sub.1-C.sub.4 alkyl,
aryl, heteroaryl, C.sub.1-C.sub.4 alkyl aryl, or C.sub.1-C.sub.4
alkyl heteroaryl; X' is O; and R.sup.6' is CH.sub.2 or
CH(C.sub.1-C.sub.4 alkyl).
8. A compound according to claim 7, wherein R.sup.1', R.sup.2',
R.sup.3', and R.sup.5' are hydrogen and R.sup.4' is
--O--R.sup.7'.
9. A compound according to claim 7, wherein R.sup.4' is
carbonylamino, sulfylamino, acyl, or carboxyl.
10. A compound according to claim 9, wherein R.sup.4' is
carbonylamino, and the carbonylamino is C(O)NHphenyl,
C(O)NH-m-pyridyl, C(O)NH-o-pyridyl, C(O)NH-p-pyridyl, C(O)NH.sub.2,
or C(O)NHCH.sub.3.
11. A compound according to claim 7, wherein R.sup.1', R.sup.2',
and R.sup.5' are H and one of R.sup.3' and R.sup.4' is
carbonylamino, sulfylamino, acyl, or carboxyl.
12. A compound according claim 7, wherein R.sup.2' or R.sup.4' is
--O--R.sup.7'.
13. A compound according to claim 12, wherein R.sup.7' is methyl,
ethyl, phenyl, benzyl, propyl, or isopropyl.
14. A method for influencing the action of a G-protein-coupled
receptor kinase in a cell comprising administering to or contacting
with the cell at least one compound according to claim 7, or
reducing GPCR desensitization in a cell comprising administering to
or contacting with the cell a therapeutically effective amount of a
compound according to claim 7, or inhibiting the action of a
G-protein-coupled receptor kinase comprising applying to a medium
or contacting with a cell an effective inhibitory amount of a
compound according to claim 7.
15. The method according to claim 14, wherein R.sup.1', R.sup.3',
and R.sup.5' are hydrogen.
16. The method according to claim 14, wherein R.sup.2' or R.sup.4'
is --O--R.sup.7'.
17. The method according to claim 14, wherein R.sup.7' is methyl,
ethyl, phenyl, benzyl, propyl, or isopropyl.
18. The method according to claim 14, wherein R.sup.2' or R.sup.4'
is carbonylamino.
19. The method according to claim 18, wherein the carbonylamino
moiety is selected from C(O)NHphenyl, C(O)NY-m-pyridyl,
C(O)NY-o-pyridyl, C(O)NY-p-pyridyl, C(O)NH.sub.2, or
C(O)NHCH.sub.3.
20. The method according to claim 14, wherein the G-protein-coupled
receptor kinase is GRK-2, GRK-3, GRK-5, or GRK-6.
21. The method according to claim 14, wherein the G-protein-coupled
receptor kinase is GRK-2.
22. A pharmaceutical composition comprising: (a) a compound
according to claim 7; and (b) a carrier.
23. The composition of claim 22, wherein the carrier is selected
from the group consisting of systemic and topical carriers.
24. The composition of claim 22, wherein the composition comprises
about 0.01% to 10% of the isoquinoline derivative and about 90 to
99.99% of the systemic carrier.
25. A method of treating a condition comprising administering to a
subject in need of treatment a safe and effective amount of an
isoquinoline derivative, wherein the condition is selected from the
group consisting of eye disease, bone disorder, heart disease,
hepatic disease, renal disease, pancreatitis, cancer, myocardial
infarct, gastric disturbance, hypertension, fertility control,
nasal congestion, neurogenic bladder disorder, gastrointestinal
disorder, and dermatological disorder, wherein the isoquinoline
derivative is a compound according to claim 1.
26. The method of claim 25, wherein the condition comprises eye
disease.
27. The method of claim 26, wherein the condition comprise
glaucoma.
28. The method of claim 25, wherein R.sup.1, R.sup.2, R.sup.3,
R.sup.4, and R.sup.5 are not phenoxy.
29. The method of claim 25, wherein the isoquinoline derivative is
according to Formula (II): ##STR00047## wherein R.sup.1, R.sup.2,
R.sup.3, R.sup.4, and R.sup.5 are, independently, hydrogen,
halogen, unsubstituted C.sub.1-C.sub.4 alkyl, amino, nitro, cyano,
carbonylamino, alkoxy, --O--R.sup.7, sulfonylamino, carboxyl, acyl,
or thioalkyl; R.sup.7 is C.sub.1-C.sub.4 alkyl, aryl, heteroaryl,
C.sub.1-C.sub.4 alkyl aryl, or C.sub.1-C.sub.4 alkyl heteroaryl; X'
is O; and R.sup.6 is CH.sub.2 or CH(C.sub.1-C.sub.4 alkyl).
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 12/274,887, filed Nov. 20, 2008, which is a continuation of
U.S. application Ser. No. 11/485,172, filed Jul. 11, 2006, now U.S.
Pat. No. 7,470,787, issued Dec. 30, 2008, which claims benefit of
U.S. Provisional Application No. 60/698,165, filed Jul. 11, 2005,
and all of which are incorporated herein by reference in their
entireties.
BACKGROUND
[0002] 1. Field of the Invention
[0003] The present invention relates to isoquinoline compounds that
may affect the action of G protein-coupled receptor kinases in a
cell and that are useful as therapeutic agents or with therapeutic
agents. In particular, these compounds are useful in the treatment
of eye diseases or ocular disorders such as glaucoma.
[0004] 2. Background
[0005] A variety of hormones, neurotransmitters and biologically
active substances control, regulate or adjust the functions of
living bodies via specific receptors located in cell membranes.
Many of these receptors mediate the transmission of intracellular
signals by activating guanine nucleotide-binding proteins (G
proteins) to which the receptor is coupled. Such receptors are
generically referred to as G-protein coupled receptors (GPCRs) and
include, among others, .alpha.-adrenergic receptors,
.beta.-adrenergic receptors, opioid receptors, cannabinoid
receptors and prostaglandin receptors.
[0006] The G-protein coupled receptors play an important role in
the regulation of various physiological functions. By way of
example, GPCRs have been implicated in a number of disease states,
including, but not limited to: cardiac indications such as angina
pectoris, essential hypertension, myocardial infarction,
supraventricular and ventricular arrhythmias, congestive heart
failure, atherosclerosis, renal failure, diabetes, respiratory
indications such as asthma, chronic bronchitis, bronchospasm,
emphysema, airway obstruction, upper respiratory indications such
as rhinitis, seasonal allergies, inflammatory disease, inflammation
in response to injury, rheumatoid arthritis, chronic inflammatory
bowel disease, glaucoma, hypergastrinemia, gastrointestinal
indications such as acid/peptic disorder, erosive esophagitis,
gastrointestinal hypersecretion, mastocytosis, gastrointestinal
reflux, peptic ulcer, Zollinger-Ellison syndrome, pain, obesity,
bulimia nervosa, depression, obsessive-compulsive disorder, organ
malformations (for example, cardiac malformations),
neurodegenerative diseases such as Parkinson's Disease and
Alzheimer's Disease, multiple sclerosis, Epstein-Barr infection and
cancer.
[0007] The balance between the initiation and the turn off of the
intracellular signal, called desensitization, regulates the
intensity and duration of the response of the receptors to stimuli
such as agonists. Desensitization of agonist-occupied GPCRs results
from their phosphorylation by specific kinases called G
protein-coupled receptor kinases (GRKs) and the subsequent binding
of arrestin proteins to phosphorylated receptors. Arrestins are a
family of intracellular proteins that bind activated GPCRs,
including those that have been agonist-activated, and especially
those that have been phosphorylated by G protein-coupled receptor
kinases. The binding of the arrestins prevents further stimulation
of G proteins and downstream signaling pathways. When
desensitization occurs, the mediation or regulation of the
physiological function mediated or regulated by the G proteins to
which the receptors are coupled is reduced or prevented. For
example, when agonists are administered to treat a disease or
condition by activation of certain receptors, the receptors become
desensitized from the action of the GRKs such that agonist
administration may no longer result in therapeutic activation of
the appropriate receptors. At that point, administration of the
agonist no longer enables sufficient or effective control of or
influence on the disease or condition intended to be treated.
[0008] In view of the role of GRKs in the desensitization of GPCRs,
there is a need in the art for agents that prevent or reduce the
desensitization of the GPCRs by controlling or inhibiting the
action of the corresponding GRKs.
SUMMARY
[0009] A compound according to Formula I is provided:
##STR00001##
wherein A is a substituted or unsubstituted isoquinoline radical
wherein the isoquinoline radical may be mono- or disubstituted with
halogen, cyano, nitro or C.sub.1-C.sub.4 alkyl; R.sup.1, R.sup.2,
R.sup.3, R.sup.4, and R.sup.5 are, independently selected from
hydrogen; halogen; C.sub.1-C.sub.4 alkyl; alkoxy; amino; nitro;
cyano; aryl; C.sub.1-C.sub.4 alkyl aryl; heteroaryl;
C.sub.1-C.sub.4 alkyl heteroaryl; carbonylamino; thioalkyl;
sulfonyl; sulfonylamino; acyl; or carboxyl; R is C.sub.1-C.sub.4
alkyl, aryl, heteroaryl, C.sub.1-C.sub.4 alkyl aryl or
C.sub.1-C.sub.4 alkyl heteroaryl;
X is O, S, S(O), S(O)(O),
##STR00002##
[0010] and R.sup.6 is CH.sub.2 or CH(C.sub.1-C.sub.4 alkyl).
[0011] An isoquinoline compound according to Formula II is further
provided:
##STR00003##
wherein R.sup.1', R.sup.2', R.sup.3', R.sup.4', and R.sup.5' are,
independently, hydrogen; halogen; unsubstituted C.sub.1-C.sub.4
alkyl; amino; nitro; cyano; carbonylamino; alkoxy; --O--R;
sulfonylamino; carboxyl; acyl; or thioalkyl; R is C.sub.1-C.sub.4
alkyl, aryl, heteroaryl, C.sub.1-C.sub.4 alkyl aryl or
C.sub.1-C.sub.4 alkyl heteroaryl;
X' is O, S, S(O), S(O)(O),
##STR00004##
[0012] and R.sup.6' is CH.sub.2 or CH(C.sub.1-C.sub.4 alkyl).
[0013] In another embodiment, compositions comprising the compounds
of formula (I) and a pharmaceutically acceptable carrier, as well
as compositions comprising the compounds of formula (II) and a
pharmaceutically acceptable carrier are provided.
[0014] In one embodiment, a pharmaceutical composition having GPCR
desensitization inhibitory activity is provided for administration
to a living organism, the pharmaceutical composition comprising a
therapeutically effective amount of a compound according to Formula
I or Formula II and a pharmaceutically acceptable carrier.
[0015] In a further embodiment, a method for influencing the action
of a G-protein-coupled receptor kinase in a cell is provided
comprising administering to or contacting with the cell at least
one compound according to Formula (II). The method may be used to
influence the action of a G-protein-coupled receptor kinase in a
cell in vitro or in a cell in vivo in a living organism.
[0016] Another embodiment provides a method of reducing GPCR
desensitization in a cell comprising administering to or contacting
with the cell a therapeutically effective amount of a compound
according to Formula (II). The method may be used to reduce GPCR
desensitization in a cell in vitro or in a cell in vivo in a living
organism.
[0017] A further embodiment provides a method of inhibiting the
action of a G-protein-coupled receptor kinase comprising applying
to a medium or contacting with a cell an effective inhibitory
amount of a compound according to Formula (II). The method may be
used to inhibit the action of a GRK in a cell in vitro or in a cell
in vivo in a living organism.
[0018] An additional embodiment provides a method of treating a
condition comprising administering to a subject in need of
treatment a safe and effective amount of an isoquinoline
derivative, wherein the condition is selected from the group
consisting of eye disease, bone disorder (such as osteoporosis),
heart disease, hepatic disease, renal disease, pancreatitis,
cancer, myocardial infarct, gastric disturbance, hypertension,
fertility control, nasal congestion, neurogenic bladder disorder, a
gastrointestinal disorder, and a dermatological disorder. In one
embodiment the condition comprises eye disease, and more
particularly, glaucoma.
BRIEF DESCRIPTION OF THE DRAWINGS
[0019] FIG. 1 is a graphical representation of the effect of a 60
minute pre-incubation of the GRK-2 inhibitor of Example 2 on
ISO-induced .beta.-arrestin translocation in .beta.2wt using a
Transfluor.RTM. assay.
[0020] FIG. 2 is a graphical representation of the effect of a 60
minute pre-incubation of the GRK-2 inhibitor of Example 2 on
ISO-induced .beta.-arrestin translocation in .beta.1wt using a
Transfluor.RTM. assay.
[0021] FIG. 3 is a graphical representation of the effect of a 60
minute pre-incubation of the GRK-2 inhibitor of Example 2 on
morphine-induced .beta.-arrestin translocation of .mu.-opioid
receptor using a Transfluor.RTM. assay.
[0022] FIG. 4 is a graphical representation of the effect of a 60
minute pre-incubation of the GRK-2 inhibitor of Example 3 on
ISO-induced (3-arrestin translocation in .beta.2wt using a
Transfluor.RTM. assay.
[0023] FIG. 5 is a graphical representation of the effect of a 60
minute pre-incubation of the GRK-2 inhibitor of Example 3 on
ISO-induced .beta.-arrestin translocation in .beta.1wt using a
Transfluor.RTM. assay.
[0024] FIG. 6 is a graphical representation of the effect of a 60
minute pre-incubation of the GRK-2 inhibitor of Example 3 on
morphine-induced .beta.-arrestin translocation of .mu.-opioid
receptor using a Transfluor.RTM. assay.
[0025] FIG. 7 is a graphical representation of the effect of a 60
minute pre-incubation of the GRK-2 inhibitor of Example 4 on
ISO-induced .beta.-arrestin translocation in .beta.2wt using a
Transfluor.RTM. assay.
[0026] FIG. 8 is a graphical representation of the effect of a 60
minute pre-incubation of the GRK-2 inhibitor of Example 4 on
ISO-induced .beta.-arrestin translocation in .beta.1wt using a
Transfluor.RTM. assay.
[0027] FIG. 9 is a graphical representation of the effect of a 60
minute pre-incubation of the GRK-2 inhibitor of Example 4 on
morphine-induced .beta.-arrestin translocation of .mu.-opioid
receptor using a Transfluor.RTM. assay.
DETAILED DESCRIPTION
[0028] Novel isoquinoline compounds and methods of using those
compounds to reduce or prevent desensitization of GPCR pathways are
provided.
[0029] "Alkyl" refers to a saturated aliphatic hydrocarbon
including straight chain and branched chain groups. "Alkyl" may be
exemplified by groups such as methyl, ethyl, n-propyl, isopropyl,
n-butyl and the like. Alkyl groups may be substituted or
unsubstituted. When substituted, the substituent group is
preferably amino, cyano, halogen, alkoxyl or hydroxyl.
"C.sub.1-C.sub.4 alkyl" refers to alkyl groups containing one to
four carbon atoms.
[0030] "Acyl" refers to the group --C(O)R wherein R is
C.sub.1-C.sub.4 alkyl, aryl, heteroaryl, C.sub.1-C.sub.4 alkyl aryl
or C.sub.1-C.sub.4 alkyl heteroaryl.
[0031] "Alkoxy" refers to the group --O-alkyl wherein alkyl has the
definition given above.
[0032] "Carboxyl" refers to the group --C(.dbd.O)O--C.sub.1-C.sub.4
alkyl.
[0033] "Carbonylamino" refers to the group --C(O)NR'R' where each
R' is, independently, hydrogen, C.sub.1-C.sub.4 alkyl, aryl,
heteroaryl, C.sub.1-C.sub.4 alkyl aryl or C.sub.1-C.sub.4 alkyl
heteroaryl.
[0034] "Aryl" refers to an aromatic carbocyclic group. "Aryl" may
be exemplified by phenyl. The aryl group may be substituted or
unsubstituted. When substituted, the substituent group is
preferably amino, cyano, halogen, or hydroxyl.
[0035] "C.sub.1-C.sub.4 alkyl aryl" refers to C.sub.1-C.sub.4 alkyl
groups having an aryl substituent such that the aryl substituent is
bonded through the alkyl group. "C.sub.1-C.sub.4 alkyl aryl" may be
exemplified by benzyl.
[0036] "C.sub.1-C.sub.4 alkyl heteroaryl" refers to C.sub.1-C.sub.4
alkyl groups having a heteroaryl substituent such that the
heteroaryl substituent is bonded through the alkyl group.
[0037] "Halogen" refers to fluoro, chloro, bromo or iodo atoms.
[0038] "Heteroaryl" refers to a mono- or disubstituted monocyclic
aromatic carbocyclic radical having one or more hetero atoms in the
carbocyclic ring, wherein the substituents may be halogen, cyano,
nitro or C.sub.1-C.sub.4 alkyl.
[0039] "Thioalkyl" refers to the group --S-alkyl.
[0040] "Sulfonyl" refers to the --S(O).sub.2R' group wherein R' is
hydrogen, C.sub.1-C.sub.1 alkyl, aryl, heteroaryl, C.sub.1-C.sub.4
alkyl aryl or C.sub.1-C.sub.4 alkyl heteroaryl.
[0041] "Sulfonylamino" refers to the --S(O).sub.2NH-- group.
[0042] "Pharmaceutically acceptable carrier" means a carrier that
is useful for the preparation of a pharmaceutical composition that
is generally compatible with the other ingredients of the
composition, not deleterious to the recipient, and neither
biologically nor otherwise undesirable. "A pharmaceutically
acceptable carrier" includes both one and more than one carrier.
Embodiments include carriers for topical, ocular, parenteral,
intravenous, intraperitoneal intramuscular, sublingual, nasal and
oral administration. "Pharmaceutically acceptable carrier" also
includes agents for preparation of aqueous dispersions and sterile
powders for injection or dispersions.
[0043] "Excipient" as used herein includes physiologically
compatible additives useful in preparation of a pharmaceutical
composition. Examples of pharmaceutically acceptable carriers and
excipients can for example be found in Remington Pharmaceutical
Science, 16.sup.th Ed.
[0044] "Therapeutically effective amount" as used herein refers to
a dosage of the compounds or compositions effective for
influencing, reducing, inhibiting or preventing desensitization of
a receptor, particularly GPCR desensitization. This term as used
herein may also refer to an amount effective at bringing about a
desired in vivo effect in an animal, preferably, a human, such as
reduction in intraocular pressure.
[0045] "Administering" as used herein refers to administration of
the compounds as needed to achieve the desired effect.
[0046] "Eye disease" as used herein includes, but is not limited
to, glaucoma, allergy and dry eye.
[0047] The term "disease or condition associated with G-protein
receptor kinase activity" is used to mean a disease or condition
resulting, in whole or in part, from the effect on GPCR(s) by one
or more GRKs.
[0048] The term "controlling the disease or condition" is used to
mean changing the effect on GPCR(s) by one or more GRKs to affect
the disease or condition.
[0049] "Desensitization" or "GPCR desensitization" refers generally
to the process by which sensitized GPCRs are converted to
desensitized GPCRs.
[0050] "Desensitized GPCR" means a GPCR that presently does not
have ability to respond to agonist and activate conventional G
protein signaling.
[0051] "Sensitized GPCR" means a GPCR that presently has ability to
respond to agonist and activate conventional G protein
signaling.
[0052] "GPCR desensitization pathway" means any cellular component
of the GPCR desensitization process, as well as any cellular
structure implicated in the GPCR desensitization process and
subsequent processes, including but not limited to, arrestins,
GRKs, GPCRs, AP-2 protein, clathrin, protein phosphatases, and the
like.
[0053] "GPCR signaling" means GPCR induced activation of G
proteins. This may result in, for example, cAMP production.
[0054] "G protein-coupled receptor kinase" (GRK) includes any
kinase that has the ability to phosphorylate a GPCR.
[0055] "GPCR desensitization inhibitory activity" of a composition
(e.g., compound, solution, etc.) means that the composition is
capable of inhibiting GPCR desensitization of at least one specific
GPCR.
[0056] The term "to inhibit the G-protein receptor kinase activity"
or "inhibit the action of a GRK" means to reduce or decrease the
action of the GRK.
[0057] The term "to influence the GRK activity" or "to influence
the action of the GRK" means to change or affect the action or
activity of a GRK on one or more GPCRs.
[0058] The isoquinoline compounds may be represented by Formula
I:
##STR00005##
wherein A is a substituted or unsubstituted isoquinoline radical
wherein the isoquinoline radical may be mono- or disubstituted with
halogen, cyano, nitro or C.sub.1-C.sub.4 alkyl; R.sup.1, R.sup.2,
R.sup.3, R.sup.4, and R.sup.5 are, independently, hydrogen;
halogen; C.sub.1-C.sub.4 alkyl; alkoxy; phenoxy; --O--R; --SR;
amino; nitro; cyano; aryl; C.sub.1-C.sub.4 alkyl aryl; heteroaryl;
C.sub.1-C.sub.4 alkyl heteroaryl; carbonylamino; thioalkyl;
sulfonyl; sulfonylamino; acyl; or carboxyl; R is C.sub.1-C.sub.4
alkyl, aryl, heteroaryl, C.sub.1-C.sub.4 alkyl aryl or
C.sub.1-C.sub.4 alkyl heteroaryl;
X is O, S, S(O), S(O)(O),
##STR00006##
[0059] and R.sup.6 is CH.sub.2 or CH(C.sub.1-C.sub.4 alkyl).
[0060] In a preferred embodiment of Formula (I), A is an
unsubstituted isoquinoline radical and R.sup.1, R.sup.3, and
R.sup.5 are hydrogen. In another preferred embodiment of Formula
(I), X is
##STR00007##
In another preferred embodiment of Formula (I), R.sup.1, R.sup.3,
and R.sup.5 are hydrogen and R.sup.2 or R.sup.4 is --O--R, as
defined above.
[0061] In another embodiment, the isoquinoline compounds may be
represented by Formula (II):
##STR00008##
wherein R.sup.1', R.sup.2', R.sup.3', R.sup.4', and R.sup.5' are,
independently, hydrogen; halogen; unsubstituted C.sub.1-C.sub.4
alkyl; amino; nitro; cyano; carbonylamino; alkoxy; --O--R; --SR;
sulfonylamino; carboxyl; acyl; phenoxy or thioalkyl; R is
C.sub.1-C.sub.4 alkyl, aryl, heteroaryl, C.sub.1-C.sub.4 alkyl aryl
or C.sub.1-C.sub.4 alkyl heteroaryl;
X' is O, S, S(O), S(O)(O),
##STR00009##
[0062] and R.sup.6' is CH.sub.2 or CH(C.sub.1-C.sub.4 alkyl).
[0063] In some preferred embodiments, the isoquinolines include
those compounds wherein R.sup.1', R.sup.3' and R.sup.5' are
hydrogen and X' is
##STR00010##
In further preferred embodiments, one of R.sup.2' or R.sup.4' is
also hydrogen. In some preferred embodiments either R.sup.2' or
R.sup.4' is hydrogen and the other R.sup.2' or R.sup.4' group is
--O-benzyl; cyano; --C(O)--NH-phenyl; hydrogen; --O-phenyl;
--S--C.sub.1-C.sub.4 alkyl, preferably --S--CH.sub.3;
--C.sub.1-C.sub.4 alkyl, preferably methyl, --C(O)--NH-m-pyridine,
--C(O--)NH.sub.2, --SO.sub.2--NH.sub.2, --C(O)O--C.sub.1-C.sub.4
alkyl, preferably --C(O)O--CH.sub.3; --C(O)phenyl;
--C(O)NH--C.sub.1-C.sub.4 alkyl, preferably --C(O)NH--CH.sub.3;
halogen, preferably chlorine or fluorine; --C(O)--C.sub.1-C.sub.4
alkyl, preferably --C(O)--CH.sub.3; or --O--C.sub.1-C.sub.4 alkyl,
preferably O--CH.sub.3 or O-propyl, preferably isopropyl. In some
preferred embodiments R.sup.2' and R.sup.4' are hydrogen and
R.sup.3' is selected from the group comprising --O-benzyl; cyano;
--C(O)--NH-phenyl; hydrogen; --O-phenyl; --S--C.sub.1-C.sub.4
alkyl, preferably --S--CH.sub.3; --C.sub.1-C.sub.4 alkyl,
preferably methyl, --C(O)--NH-m-pyridine, --C(O--)NH.sub.2,
--SO.sub.2--NH.sub.2, --C(O)O--C.sub.1-C.sub.4 alkyl, preferably
--C(O)O--CH.sub.3; --C(O)aryl; --C(O)NH--C.sub.1-C.sub.4 alkyl,
preferably --C(O)NH--CH.sub.3; halogen, --C(O)--C.sub.1-C.sub.4
alkyl, preferably --C(O)--CH.sub.3; or --O--C.sub.1-C.sub.4 alkyl,
preferably O--CH.sub.3 or O-propyl, preferably isopropyl.
[0064] The isoquinoline compounds may be synthesized by the general
schemes set forth below:
##STR00011##
[0065] Scheme 1: The corresponding substituted aniline was treated
with a suitable protecting group such as tert-butoxycarbonyl,
followed by reaction with a suitable electrophile in a non-protic
solvent in the presence of an appropriate base such as NaH.
Saponification of the glycine ester derivative yields the
appropriate carboxylic acid, which can be coupled to
6-aminoisoquinoline using standard amide coupling procedures to
provide substituted aminoisoquinoline. Removal of the protecting
group following established protocols for such transformations
provides the final isoquinoline derivatives.
##STR00012##
[0066] Scheme 2: Alternatively, compounds of the invention may be
prepared via the method described in Scheme 2. 6-Aminoisoquinoline
can be acylated using the appropriate acylating agent in a
non-protic solvent with an appropriate base. Use of LDA as the base
and chloroacetyl chloride gives a chloroacetamide derivative.
Treatment of this material with the corresponding substituted
aniline in an appropriate solvent and optionally heating the
reaction affords the final isoquinoline derivatives.
[0067] The R.sup.a group generally represents the substituents as
set forth in either Formula I or Formula II for groups R.sup.1,
R.sup.2, R.sup.3, R.sup.4, and R.sup.5 or R.sup.1', R.sup.2',
R.sup.3', R.sup.4', and R.sup.5'. The abbreviations used in the
synthesis schemes shown have the following meanings: Boc.sub.2O
means di-tert-butyl-dicarbonate, HATU means
2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate, LDA means lithium diisopropyl amide, DMF is
dimethylformamide, and THF is tetrahydrofuran.
[0068] The isoquinoline compounds of Formula (I) or Formula (II)
and compositions including them have GPCR desensitization
inhibitory activity and may be useful in influencing or inhibiting
the action of G-protein receptor kinases, influencing, preventing
or reducing the desensitization of receptors phosphorylated by
G-protein receptor kinases, influencing or inhibiting other
GRK-mediated events and in treatment and/or prevention of diseases
or conditions controlled by receptors affected by one or more of
the G-protein receptor kinases. The isoquinolines may be used to
influence or inhibit the action of GRKs either in a cell in vitro
or in a cell in a living body in vivo. Specifically, in one
embodiment, a method is provided of inhibiting the action of a
G-protein-coupled receptor kinase comprising applying to a medium
such as an assay medium or contacting with a cell either in a cell
in vitro or in a cell in a living body in vivo an effective
inhibitory amount of a compound according to Formula (I) or (II).
In a preferred embodiment, the GRK inhibited is GRK-2, GRK-3, GRK-5
or GRK-6. In a further preferred embodiment, the GRK inhibited is
GRK-2.
[0069] In one embodiment, the isoquinolines according to Formulas I
or II are used in methods of reducing GPCR desensitization in a
cell comprising administering to, or contacting with, the cell a
therapeutically effective amount of one or more of the
isoquinolines. The one or more of the isoquinolines are preferably
administered in a pharmaceutically acceptable formulation, such as
in or with a pharmaceutically acceptable carrier when the
isoquinolines are administered to a cell or cells in a living
organism or body. In another embodiment, the isoquinolines
according to Formulas I or II are used in methods for influencing
the action of a G-protein-coupled receptor kinase in a cell
comprising administering to, or contacting with, the cell an
effective amount of one or more isoquinolines for influencing the
action of the GRK in the cell. The one or more of the isoquinolines
are preferably administered in a pharmaceutically acceptable
formulation, such as in or with a pharmaceutically acceptable
carrier when the isoquinolines are administered to a cell or cells
in a living organism or body.
[0070] Treatment or prevention of diseases or conditions for which
the isoquinolines may be useful include any of the diseases or
conditions associated with G-protein receptor kinase activity or
diseases or conditions affected by GRK-mediated desensitization of
GPCRs. By way of example, continuous exposure to endogenous stimuli
can cause down-regulation and loss of response of beneficial GPCRs
in certain hereditary as well as most chronic diseases. Examples of
this type of disease behavior include the down-regulation and loss
of response by both .beta.-1 and .beta.-2 adrenergic receptors in
congestive heart failure. Desensitization via down-regulation of
the receptors is also seen with exogenous administration of
agonists or drugs such as morphine for pain or salbutamol for
asthma, for example, in which desensitization of the receptors
results in an undesired adverse effect known as drug tolerance. The
isoquinolines may be used to influence or reduce the GRK-controlled
desensitization for conditions affected by the action or activity
of GRKs, resulting in a therapeutic effect.
[0071] The isoquinolines in some embodiments will be administered
in conjunction with the administration of a therapeutic agent which
is directed to influencing or controlling specific G-protein
coupled receptors for the treatment or prevention of a condition or
disease affected by those specific receptors. Combining
administration of the isoquinolines with a GPCR-directed
therapeutic agent will provide a reduction or prevention of
desensitization of the receptors to which the therapeutic agent is
directed, resulting in improving the ability of the therapeutic
agent to have the desired effect over a longer period of time.
Additionally, the administration of the therapeutic agent or
receptor agonist with an isoquinoline formulation will enable lower
doses of the therapeutic agent to be administered for a longer
period of time.
[0072] One or more therapeutic agents may be administered with one
or more isoquinoline compounds. The therapeutic agents and/or the
isoquinoline compounds are preferably administered in a
pharmaceutically acceptable formulation with a pharmaceutically
acceptable carrier when the isoquinolines are administered to a
cell or cells in a living organism or body.
[0073] Compositions including the isoquinolines of Formulae I or II
may be obtained in the form of various salts or solvates. As the
salts, physiologically acceptable salts or salts available as raw
materials are used.
[0074] Pharmaceutical compositions for use in accordance with the
present invention may be formulated in a conventional manner using
one or more physiologically acceptable carriers or excipients.
Thus, the compounds and their physiologically acceptable salts and
solvates may be formulated for administration by, for example,
eyedrop, in a topical oil-based formulation, injection, inhalation
(either through the mouth or the nose), oral, buccal, parenteral or
rectal administration. Techniques and formulations may generally be
found in "Reminington's Pharmaceutical Sciences", (Meade Publishing
Co., Easton, Pa.). Therapeutic compositions must typically be
sterile and stable under the conditions of manufacture and
storage.
[0075] Compositions of the present invention may comprise a safe
and effective amount of the subject compounds, and a
pharmaceutically-acceptable carrier. As used herein, "safe and
effective amount" means an amount of a compound sufficient to
significantly induce a positive modification in the condition to be
treated, but low enough to avoid serious side effects (at a
reasonable benefit/risk ratio), within the scope of sound medical
judgment. A safe and effective amount of a compound will vary with
the particular condition being treated, the age and physical
condition of the patient being treated, the severity of the
condition, the duration of the treatment, the nature of concurrent
therapy, the particular pharmaceutically-acceptable carrier
utilized, and like factors within the knowledge and expertise of
the attending physician.
[0076] The route by which the compounds of the present invention
(component A) will be administered and the form of the composition
will dictate the type of carrier (component B) to be used. The
composition may be in a variety of forms, suitable, for example,
for systemic administration (e.g., oral, rectal, nasal, sublingual,
buccal, or parenteral) or topical administration (e.g., local
application on the skin, ocular, liposome delivery systems, or
iontophoresis).
[0077] Carriers for systemic administration typically comprise at
least one of a) diluents, b) lubricants, c) binders, d)
disintegrants, e) colorants, f) flavors, g) sweeteners, h)
antioxidants, j) preservatives, k) glidants, m) solvents, n)
suspending agents, o) wetting agents, p) surfactants, combinations
thereof, and others. All carriers are optional in the systemic
compositions.
[0078] Ingredient a) is a diluent. Suitable diluents for solid
dosage forms include sugars such as glucose, lactose, dextrose, and
sucrose; diols such as propylene glycol; calcium carbonate; sodium
carbonate; sugar alcohols, such as glycerin; mannitol; and
sorbitol. The amount of ingredient a) in the systemic composition
is typically about 50 to about 90%.
[0079] Ingredient b) is a lubricant. Suitable lubricants for solid
dosage forms are exemplified by solid lubricants including silica,
talc, stearic acid and its magnesium salts and calcium salts,
calcium sulfate; and liquid lubricants such as polyethylene glycol
and vegetable oils such as peanut oil, cottonseed oil, sesame oil,
olive oil, corn oil and oil of theobroma. The amount of ingredient
b) in the systemic composition is typically about 5 to about
10%.
[0080] Ingredient c) is a binder. Suitable binders for solid dosage
forms include polyvinylpyrrolidone; magnesium aluminum silicate;
starches such as corn starch and potato starch; gelatin;
tragacanth; and cellulose and its derivatives, such as sodium
carboxymethylcellulose, ethyl cellulose, methylcellulose,
microcrystalline cellulose, and sodium carboxymethylcellulose. The
amount of ingredient c) in the systemic composition is typically
about 5 to about 50%.
[0081] Ingredient d) is a disintegrant. Suitable disintegrants for
solid dosage forms include agar, alginic acid and the sodium salt
thereof, effervescent mixtures, croscarmelose, crospovidone, sodium
carboxymethyl starch, sodium starch glycolate, clays, and ion
exchange resins. The amount of ingredient d) in the systemic
composition is typically about 0.1 to about 10%.
[0082] Ingredient e) for solid dosage forms is a colorant such as
an FD&C dye. The amount of ingredient e) in the systemic
composition is typically about 0.005 to about 0.1%.
[0083] Ingredient f) for solid dosage forms is a flavor such as
menthol, peppermint, and fruit flavors. The amount of ingredient f)
in the systemic composition is typically about 0.1 to about
1.0%.
[0084] Ingredient g) for solid dosage forms is a sweetener such as
aspartame and saccharin. The amount of ingredient g) in the
systemic composition is typically about 0.001 to about 1%.
[0085] Ingredient h) is an antioxidant such as butylated
hydroxyanisole ("BHA"), butylated hydroxytoluene ("BHT"), and
vitamin E. The amount of ingredient h) in the systemic composition
is typically about 0.1 to about 5%.
[0086] Ingredient j) is a preservative such as benzalkonium
chloride, methyl paraben and sodium benzoate. The amount of
ingredient j) in the systemic composition is typically about 0.01
to about 5%.
[0087] Ingredient k) for solid dosage forms is a glidant such as
silicon dioxide. The amount of ingredient k) in the systemic
composition is typically about 1 to about 5%.
[0088] Ingredient m) is a solvent, such as water, isotonic saline,
ethyl oleate, alcohols such as ethanol, and phosphate buffer
solutions. The amount of ingredient m) in the systemic composition
is typically from about 0 to about 100%.
[0089] Ingredient n) is a suspending agent. Suitable suspending
agents include AVICEL.RTM. RC-591 (from FMC Corporation of
Philadelphia, Pa.) and sodium alginate. The amount of ingredient n)
in the systemic composition is typically about 1 to about 8%.
[0090] Ingredient o) is a surfactant such as lecithin, polysorbate
80, and sodium lauryl sulfate, and the TWEENS.RTM. from Atlas
Powder Company of Wilmington, Del. Suitable surfactants include
those disclosed in the C.T.F.A. Cosmetic Ingredient Handbook, 1992,
pp. 587-592; Remington's Pharmaceutical Sciences, 15th Ed. 1975,
pp. 335-337; and McCutcheon's Volume 1, Emulsifiers &
Detergents, 1994, North American Edition, pp. 236-239. The amount
of ingredient o) in the systemic composition is typically about
0.1% to about 2%.
[0091] Although the amounts of components A and B in the systemic
compositions will vary depending on the type of systemic
composition prepared, the specific derivative selected for
component A and the ingredients of component B, in general, system
compositions comprise 0.01% to 50% of component A and 50 to 99.99%
of component B.
[0092] Compositions for parenteral administration typically
comprise A) 0.1 to 10% of the compounds of the present invention
and B) 90 to 99.9% of a carrier comprising a) a diluent and m) a
solvent. In one embodiment, component a) comprises propylene glycol
and m) comprises ethanol or ethyl oleate.
[0093] Compositions for oral administration can have various dosage
forms. For example, solid forms include tablets, capsules,
granules, and bulk powders. These oral dosage forms comprise a safe
and effective amount, usually at least about 5%, and more
particularly from about 25% to about 50% of component A). The oral
dosage compositions further comprise about 50 to about 95% of
component B), and more particularly, from about 50 to about
75%.
[0094] Tablets can be compressed, tablet triturates,
enteric-coated, sugar-coated, film-coated, or multiple-compressed.
Tablets typically comprise component A, and component B a carrier
comprising ingredients selected from the group consisting of a)
diluents, b) lubricants, c) binders, d) disintegrants, e)
colorants, f) flavors, g) sweeteners, k) glidants, and combinations
thereof. Specific diluents include calcium carbonate, sodium
carbonate, mannitol, lactose and cellulose. Specific binders
include starch, gelatin, and sucrose. Specific disintegrants
include alginic acid and croscarmelose. Specific lubricants include
magnesium stearate, stearic acid, and talc. Specific colorants are
the FD&C dyes, which can be added for appearance. Chewable
tablets preferably contain g) sweeteners such as aspartame and
saccharin, or f) flavors such as menthol, peppermint, fruit
flavors, or a combination thereof.
[0095] Capsules (including time release and sustained release
formulations) typically comprise component A, and a carrier
comprising one or more a) diluents disclosed above in a capsule
comprising gelatin. Granules typically comprise component A, and
preferably further comprise k) glidants such as silicon dioxide to
improve flow characteristics.
[0096] The selection of ingredients in the carrier for oral
compositions depends on secondary considerations like taste, cost,
and shelf stability, which are not critical for the purposes of
this invention. One skilled in the art would know how to select
appropriate ingredients without undue experimentation.
[0097] The solid compositions may also be coated by conventional
methods, typically with pH or time-dependent coatings, such that
component A is released in the gastrointestinal tract in the
vicinity of the desired application, or at various points and times
to extend the desired action. The coatings typically comprise one
or more components selected from the group consisting of cellulose
acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl
methyl cellulose phthalate, ethyl cellulose, EUDRAGIT.RTM. coatings
(available from Rohm & Haas G.M.B.H. of Darmstadt, Germany),
waxes and shellac.
[0098] Compositions for oral administration can also have liquid
forms. For example, suitable liquid forms include aqueous
solutions, emulsions, suspensions, solutions reconstituted from
non-effervescent granules, suspensions reconstituted from
non-effervescent granules, effervescent preparations reconstituted
from effervescent granules, elixirs, tinctures, syrups, and the
like. Liquid orally administered compositions typically comprise
component A and component B, namely, a carrier comprising
ingredients selected from the group consisting of a) diluents, e)
colorants, f) flavors, g) sweeteners, j) preservatives, m)
solvents, n) suspending agents, and o) surfactants. Peroral liquid
compositions preferably comprise one or more ingredients selected
from the group consisting of e) colorants, f) flavors, and g)
sweeteners.
[0099] Other compositions useful for attaining systemic delivery of
the subject compounds include sublingual, buccal and nasal dosage
forms. Such compositions typically comprise one or more of soluble
filler substances such as a) diluents including sucrose, sorbitol
and mannitol; and c) binders such as acacia, microcrystalline
cellulose, carboxymethyl cellulose, and hydroxypropyl
methylcellulose. Such compositions may further comprise b)
lubricants, e) colorants, f) flavors, g) sweeteners, h)
antioxidants, and k) glidants.
[0100] In one embodiment of the invention, the compounds of the
present invention are topically administered. Topical compositions
that can be applied locally to the eye may be in any form known in
the art, non-limiting examples of which include gelable drops,
spray, ointment, or a sustained or non-sustained release unit
placed in the conjunctival cul-du-sac of the eye.
[0101] Topical compositions that can be applied locally to the skin
may be in any form including solutions, oils, creams, ointments,
gels, lotions, shampoos, leave-on and rinse-out hair conditioners,
milks, cleansers, moisturizers, sprays, skin patches, and the like.
Topical compositions comprise: component A, the compounds described
above, and component B, a carrier. The carrier of the topical
composition preferably aids penetration of the compounds into the
eye. Component B may further comprise one or more optional
components.
[0102] The dosage range of the compound for systemic administration
is from about 0.01 to about 1000 .mu.g/kg body weight, preferably
from about 0.1 to about 100 .mu.g/kg per body weight, most
preferably form about 1 to about 50 .mu.g/kg body weight per day.
The transdermal dosages will be designed to attain similar serum or
plasma levels, based upon techniques known to those skilled in the
art of pharmacokinetics and transdermal formulations. Plasma levels
for systemic administration are expected to be in the range of 0.01
to 100 nanograms/ml, more preferably from 0.05 to 50 ng/ml, and
most preferably from 0.1 to 10 ng/ml. While these dosages are based
upon a daily administration rate, weekly or monthly accumulated
dosages may also be used to calculate the clinical
requirements.
[0103] Dosages may be varied based on the patient being treated,
the condition being treated, the severity of the condition being
treated, the route of administration, etc. to achieve the desired
effect.
[0104] The compounds of the present invention are also useful in
decreasing intraocular pressure. Thus, these compounds are useful
in the treatment of glaucoma. The preferred route of administration
for treating glaucoma is topically.
[0105] The exact amounts of each component in the topical
composition depend on various factors. The amount of component A
added to the topical composition is dependent on the IC.sub.50 of
component A, typically expressed in nanomolar (nM) units. For
example, if the IC.sub.50 of the medicament is 1 nM, the amount of
component A will be from about 0.0001 to about 0.01%. If the
IC.sub.50 of the medicament is 10 nM, the amount of component A)
will be from about 0.001 to about 0.1%. If the IC.sub.50 of the
medicament is 100 nM, the amount of component A will be from about
0.01 to about 1.0%. If the IC.sub.50 of the medicament is 1000 nM,
the amount of component A will be 0.1 to 10%, preferably 0.5 to
5.0%. If the amount of component A is outside the ranges specified
above (i.e., either higher or lower), efficacy of the treatment may
be reduced. IC.sub.50 can be calculated according to the method in
Reference Example 1, below. One skilled in the art would know how
to calculate an IC.sub.50. The remainder of the composition, up to
100%, is component B.
[0106] The amount of the carrier employed in conjunction with
component A is sufficient to provide a practical quantity of
composition for administration per unit dose of the medicament.
Techniques and compositions for making dosage forms useful in the
methods of this invention are described in the following
references: Modern Pharmaceutics, Chapters 9 and 10, Banker &
Rhodes, eds. (1979); Lieberman et al., Pharmaceutical Dosage Forms:
Tablets (1981); and Ansel, Introduction to Pharmaceutical Dosage
Forms, 2.sup.nd Ed., (1976).
[0107] Component B may comprise a single ingredient or a
combination of two or more ingredients. In the topical
compositions, component B comprises a topical carrier. Suitable
topical carriers comprise one or more ingredients selected from the
group consisting of phosphate buffered saline, isotonic water,
deionized water, monofunctional alcohols, symmetrical alcohols,
aloe vera gel, allantoin, glycerin, vitamin A and E oils, mineral
oil, propylene glycol, PPG-2 myristyl propionate, dimethyl
isosorbide, castor oil, combinations thereof, and the like. More
particularly, carriers for skin applications include propylene
glycol, dimethyl isosorbide, and water, and even more particularly,
phosphate buffered saline, isotonic water, deionized water,
monofunctional alcohols and symmetrical alcohols.
[0108] The carrier of the topical composition may further comprise
one or more ingredients selected from the group consisting of q)
emollients, r) propellants, s) solvents, t) humectants, u)
thickeners, v) powders, w) fragrances, x) pigments, and y)
preservatives.
[0109] Ingredient q) is an emollient. The amount of ingredient q)
in a skin-based topical composition is typically about 5 to about
95%. Suitable emollients include stearyl alcohol, glyceryl
monoricinoleate, glyceryl monostearate, propane-1,2-diol,
butane-1,3-diol, mink oil, cetyl alcohol, isopropyl isostearate,
stearic acid, isobutyl palmitate, isocetyl stearate, oleyl alcohol,
isopropyl laurate, hexyl laurate, decyl oleate, octadecan-2-ol,
isocetyl alcohol, cetyl palmitate, di-n-butyl sebacate, isopropyl
myristate, isopropyl palmitate, isopropyl stearate, butyl stearate,
polyethylene glycol, triethylene glycol, lanolin, sesame oil,
coconut oil, arachis oil, castor oil, acetylated lanolin alcohols,
petroleum, mineral oil, butyl myristate, isostearic acid, palmitic
acid, isopropyl linoleate, lauryl lactate, myristyl lactate, decyl
oleate, myristyl myristate, and combinations thereof. Specific
emollients for skin include stearyl alcohol and
polydimethylsiloxane.
[0110] Ingredient r) is a propellant. The amount of ingredient r)
in the topical composition is typically about 0 to about 95%.
Suitable propellants include propane, butane, isobutane, dimethyl
ether, carbon dioxide, nitrous oxide, and combinations thereof.
[0111] Ingredient s) is a solvent. The amount of ingredient s) in
the topical composition is typically about 0 to about 95%. Suitable
solvents include water, ethyl alcohol, methylene chloride,
isopropanol, castor oil, ethylene glycol monoethyl ether,
diethylene glycol monobutyl ether, diethylene glycol monoethyl
ether, dimethylsulfoxide, dimethyl formamide, tetrahydrofuran, and
combinations thereof. Specific solvents include ethyl alcohol and
homotopic alcohols.
[0112] Ingredient t) is a humectant. The amount of ingredient t) in
the topical composition is typically 0 to 95%. Suitable humectants
include glycerin, sorbitol, sodium 2-pyrrolidone-5-carboxylate,
soluble collagen, dibutyl phthalate, gelatin, and combinations
thereof. Specific humectants include glycerin.
[0113] Ingredient u) is a thickener. The amount of ingredient u) in
the topical corn-position is typically about 0 to about 95%.
[0114] Ingredient v) is a powder. The amount of ingredient v) in
the topical composition is typically 0 to 95%. Suitable powders
include beta-cyclodextrins, hydroxypropyl cyclodextrins, chalk,
talc, fullers earth, kaolin, starch, gums, colloidal silicon
dioxide, sodium polyacrylate, tetra alkyl ammonium smectites,
trialkyl aryl ammonium smectites, chemically-modified magnesium
aluminum silicate, organically-modified montmorillonite clay,
hydrated aluminum silicate, fumed silica, carboxyvinyl polymer,
sodium carboxymethyl cellulose, ethylene glycol monostearate, and
combinations thereof. For ocular applications, specific powders
include beta-cyclodextrin, hydroxypropyl cyclodextrin, and sodium
polyacrylate. For gel dosing ocular formulations, sodium
polyacrylate may be used.
[0115] Ingredient w) is a fragrance. The amount of ingredient w) in
the topical composition is typically about 0 to about 0.5%,
particularly, about 0.001 to about 0.1%. For ocular applications a
fragrance is not generally used.
[0116] Ingredient x) is a pigment. Suitable pigments for skin
applications include inorganic pigments, organic lake pigments,
pearlescent pigments, and mixtures thereof. Inorganic pigments
useful in this invention include those selected from the group
consisting of rutile or anatase titanium dioxide, coded in the
Color Index under the reference CI 77,891; black, yellow, red and
brown iron oxides, coded under references CI 77,499, 77,492 and,
77,491; manganese violet (CI 77,742); ultramarine blue (CI77,007);
chromium oxide (CI77,288); chromium hydrate (CI77,289); and ferric
blue (CI77,510) and mixtures thereof.
[0117] The organic pigments and lakes useful in this invention
include those selected from the group consisting of D&C Red No.
19 (CI45,170), D&C Red No. 9 (CI 15,585), D&C Red No. 21
(CI45,380), D&C Orange No. 4 (CI 15,510), D&C Orange No. 5
(CI45,370), D&C Red No. 27 (CI45,410), D&C Red No. 13 (CI
15,630), D&C Red No. 7 (CI 15,850), D&C Red No. 6 (CI
15,850), D&C Yellow No. 5 (CI 19,140), D&C Red No. 36 (CI
12,085), D&C Orange No. 10 (CI45,425), D&C Yellow No. 6 (CI
15,985), D&C Red No. 30 (CI73,360), D&C Red No. 3 (CI
45,430), the dye or lakes based on Cochineal Carmine (CI75,570) and
mixtures thereof.
[0118] The pearlescent pigments useful in this invention include
those selected from the group consisting of the white pearlescent
pigments such as mica coated with titanium oxide, bismuth
oxychloride, colored pearlescent pigments such as titanium mica
with iron oxides, titanium mica with ferric blue, chromium oxide
and the like, titanium mica with an organic pigment of the
above-mentioned type as well as those based on bismuth oxychloride
and mixtures thereof. The amount of pigment in the topical
composition is typically about 0 to about 10%. For ocular
applications a pigment is not generally used.
[0119] In a particularly preferred embodiment of the invention,
topical pharmaceutical compositions for ocular administration are
prepared typically comprising component A and B (a carrier), such
as purified water, and one or more ingredients selected from the
group consisting of y) sugars or sugar alcohols such as dextrans,
particularly dextran 70, z) cellulose or a derivative thereof, aa)
a salt, bb) disodium EDTA (Edetate disodium), and cc) a pH
adjusting additive.
[0120] Examples of z) cellulose derivatives suitable for use in the
topical pharmaceutical composition for ocular administration
include sodium carboxymethylcellulose, ethylcellulose,
methylcellulose, and hydroxypropyl-methylcellulose, particularly,
hydroxypropyl-methylcellulose.
[0121] Examples of aa) salts suitable for use in the topical
pharmaceutical composition for ocular administration include mono-,
di- and trisodium phosphate, sodium chloride, potassium chloride,
and combinations thereof.
[0122] Examples of cc) pH adjusting additives include HCl or NaOH
in amounts sufficient to adjust the pH of the topical
pharmaceutical composition for ocular administration to
6.8-7.5.
[0123] Component A may be included in kits comprising component A,
a systemic or topical composition described above, or both; and
information, instructions, or both that use of the kit will provide
treatment for cosmetic and medical conditions in mammals
(particularly humans). The information and instructions may be in
the form of words, pictures, or both, and the like. In addition or
in the alternative, the kit may comprise the medicament, a
composition, or both; and information, instructions, or both,
regarding methods of application of medicament, or of composition,
preferably with the benefit of treating or preventing cosmetic and
medical conditions in mammals (e.g., humans).
[0124] The invention will be further explained by the following
illustrative examples that are intended to be non-limiting.
[0125] Procedures for preparation of the isoquinolines are
described in the following examples.
[0126] All temperatures are given in degrees Centigrade. Reagents
were purchased from commercial sources or prepared following
literature procedures.
[0127] Unless otherwise noted, HPLC purification was performed by
redissolving the residue in a small volume of DMSO and filtering
through a 0.45 micron (nylon disc) syringe filter. The solution was
then purified using a 50 mm Varian Dynamax HPLC 21.4 mm Microsorb
Guard-8 C.sub.8 column. The initial concentration of 40-80%
MeOH:H.sub.2O was selected as appropriate for the target compound.
This initial gradient was maintained for 0.5 minutes then increased
to 100% MeOH:0% H.sub.2O over 5 minutes. 100% MeOH was maintained
for 2 more minutes before it was re-equilibrated back to the
initial starting gradient. Total run time was 8 minutes. The
resulting fractions were analyzed, combined as appropriate, and
then evaporated to provide purified material.
[0128] Proton magnetic resonance ('H NMR) spectra were recorded on
either a Varian INOVA 400 MHz (.sup.1H) NMR spectrometer, Varian
INOVA 500 MHz (.sup.1H) NMR spectrometer, Bruker ARX 300 MHz
(.sup.1H) NMR spectrometer, Bruker DPX 400 MHz (.sup.1H) NMR
spectrometer, or a Bruker DRX 500 MHz (.sup.1H) NMR spectrometer.
All spectra were determined in the solvents indicated. Although
chemical shifts are reported in ppm downfield of tetramethylsilane,
they are referenced to the residual proton peak of the respective
solvent peak for .sup.1H NMR. Interproton coupling constants are
reported in Hertz (Hz). Analytical HPLC was performed using a
Phenomenex Aqua 5 micron C.sub.18 125 .ANG. 50.times.4.60 mm column
coupled with an Agilent 1100 series VWD UV detector. A neutral 0.1%
BES (w/v) pH 7.1 buffer with LiOH and 1% CH.sub.3CN in H.sub.2O is
used as the aqueous phase. The initial gradient was 55% MeOH
aqueous buffer which was increased to 100% MeOH over 3 minutes.
100% MeOH was maintained for 2 minutes before it was
re-equilibrated to the initial starting gradient. Spectra were
analyzed at 254 nm. LCMS spectra were obtained using a
Thermofinnigan AQA MS ESI instrument. The samples were passed
through a Phenomenex Aqua 5 micron C.sub.18 125 .ANG. 50.times.4.60
mm column. The initial gradient was 55% MeOH: 1% CH.sub.3CN in
H.sub.2O which was increased to 100% MeOH over 3 minutes. 100% MeOH
was maintained for 2 minutes before it was re-equilibrated to the
initial starting gradient. The spray setting for the MS probe was
at 350 .mu.L/min with a cone voltage at 25 mV and a probe
temperature at 450.degree. C.
[0129] The following preparations illustrate procedures for the
preparation of intermediates and methods for the preparation of
isoquinolines.
General Procedure for the Synthesis of Isoquinolines According to
Scheme 2
[0130] Step 1: Synthesis of 2-Chloro-N-isoquinolin-6-yl-acetamide:
A 2.0-mL vial equipped with a stirrer bar was charged with
6-aminoisoquinoline (100 mg, 0.7 mmol) in THF (1.0 mL) and cooled
to -78.degree. C. Lithium diisopropylamine (40 .mu.L, 0.35 mmol)
was added to the reaction at -78.degree. C. followed by dropwise
addition of chloroacetylchloride (62 .mu.L, 0.7 mmol). The reaction
was allowed to warm to room temperature and stirred for 30 min. The
reaction was concentrated in vacuo then the solid was triturated
with cold methanol. The solid was collected by filtration to afford
2-chloro-N-isoquinolin-6-yl-acetamide (58 mg, 38%). .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 3.14 (s, 2H) 8.01 (dd, J=9.08,
1.66 Hz, 1H) 8.45 (d, J=8.98 Hz, 2H) 8.66 (d, J=1.56 Hz, 1H) 11.46
(s, 1H); LCMS: 221 (M+H).
[0131] Step 2: Synthesis of Isoquinolines: A 1.0 mL vial equipped
with a stirrer bar was charged with
2-chloro-N-isoquinolin-6-yl-acetamide (See Step 1, 30 mg, 0.14
mmol), DMF (1.0 mL), potassium iodide (70 mg, 0.42 mmol) and
stirred at 45.degree. C. for 30 min. The corresponding substituted
aniline (0.42 mmol) was added and stirred for 2 h. Upon completion
the reaction was concentrated in vacuo and the residue was purified
by prep-HPLC to afford the final isoquinoline.
Example 1
##STR00013##
[0133] 2-(3-Benzyloxy-phenylamino)-N-isoquinolin-6-yl-acetamide:
The title compound was obtained as described in Step 2: .sup.1H NMR
(400 MHz, METHANOL-d.sub.4) .delta. ppm 3.93-3.97 (m, 2H) 4.99-5.02
(m, 2H) 6.27-6.33 (m, 2H) 6.33-6.39 (m, 1H) 7.04 (t, J=8.09 Hz, 1H)
7.16-7.41 (m, 6H) 7.68-7.76 (m, 2H) 8.02 (d, J=8.89 Hz, 1H)
8.31-8.37 (m, 2H) 9.09 (s, 1H); LCMS: 384 (M+H).
Example 2
##STR00014##
[0135] N-Isoquinolin-6-yl-2-(3-methoxy-phenylamino)-acetamide: The
title compound was obtained as described in Step 2: .sup.1H NMR
(400 MHz, METHANOL-d.sub.4) .delta. ppm 3.71 (s, 3H) 3.95 (s, 2H)
6.21-6.33 (m, 2H) 7.04 (t, J=8.00 Hz, 1H) 7.66-7.76 (m, 2H) 8.01
(d, J=8.98 Hz, 1H) 8.29-8.37 (m, 2H) 9.08 (s, 1H); LCMS: 308
(M+H).
Example 3
##STR00015##
[0137] 2-(3-Cyano-phenylamino)-N-isoquinolin-6-yl-acetamide: The
title compound was obtained as described in Step 2: .sup.1H NMR
(400 MHz, METHANOL-d.sub.4) .delta. ppm 4.04 (s, 2H) 6.92-7.02 (m,
3H) 7.25-7.34 (m, 1H) 7.75 (dd, J=8.88, 2.05 Hz, 2H) 8.05 (d,
J=8.98 Hz, 1H) 8.36 (d, J=1.95 Hz, 2H) 9.10 (s, 1H); LCMS: 303
(M+H).
Example 4
##STR00016##
[0139]
3-[(Isoquinolin-6-ylcarbamoylmethyl)-amino]-N-phenyl-benzamide: The
title compound was obtained as described in Step 2: .sup.1H NMR
(400 MHz, METHANOL-d.sub.4) .delta. ppm 4.07 (s, 2H) 7.09-7.14 (m,
1H) 7.22-7.25 (m, 2H) 7.27-7.36 (m, 4H) 7.61-7.66 (m, 2H) 7.71 (d,
J=5.86 Hz, 1H) 7.75 (dd, J=8.88, 2.05 Hz, 1H) 8.03 (d, J=8.98 Hz,
1H) 8.32-8.35 (m, 1H) 8.36 (d, J=1.95 Hz, 1H) 9.09 (s, 1H); LCMS:
397 (M+H).
Example 5
##STR00017##
[0141] 2-(3-Chloro-phenylamino)-N-isoquinolin-6-yl-acetamide: The
title compound was obtained as described in Step 2: .sup.1H NMR
(400 MHz, METHANOL-d.sub.4) .delta. ppm 3.99 (s, 2H) 6.56-6.60 (m,
1H) 6.63-6.69 (m, 2H) 7.09 (t, J=8.00 Hz, 1H) 7.70-7.77 (m, 2H)
8.04 (d, J=8.98 Hz, 1H) 8.32-8.37 (m, 2H) 9.09 (s, 1H); LCMS: 312
(M+H).
Example 6
##STR00018##
[0143] N-Isoquinolin-6-yl-2-phenylamino-acetamide: The title
compound was obtained as described in Step 2: .sup.1H NMR (400 MHz,
METHANOL-d.sub.4) .delta. ppm 3.97 (s, 2H) 6.65-6.75 (m, 3H)
7.10-7.19 (m, 2H) 7.67-7.78 (m, 2H) 8.02 (d, J=8.98 Hz, 1H)
8.30-8.38 (m, 2H) 9.09 (s, 1H); LCMS: 278 (M+H).
Example 7
##STR00019##
[0145] N-Isoquinolin-6-yl-2-(3-phenoxy-phenylamino)-acetamide: The
title compound was obtained as described in Step 2: .sup.1H NMR
(400 MHz, METHANOL-d.sub.4) .delta. ppm 3.93-3.95 (m, 2H) 6.28-6.33
(m, 2H) 6.42-6.48 (m, 1H) 6.91-6.96 (m, 2H) 6.99 (t, J=7.32 Hz, 1H)
7.08-7.15 (m, 1H) 7.19-7.25 (m, 2H) 7.69-7.74 (m, 2H) 8.03 (d,
J=8.79 Hz, 1H) 8.31-8.38 (m, 2H) 9.10 (s, 1H); LCMS: 370 (M+H).
Example 8
##STR00020##
[0147]
N-Isoquinolin-6-yl-2-(3-methylsulfanyl-phenylamino)-acetamide: The
title compound was obtained as described in Step 2: .sup.1H NMR
(400 MHz, METHANOL-d.sub.4) .delta. ppm 2.40 (s, 3H) 3.97 (s, 2H)
6.43-6.48 (m, 1H) 6.58-6.62 (m, 2H) 7.03-7.10 (m, 1H) 7.68-7.76 (m,
2H) 8.02 (d, J=8.98 Hz, 1H) 8.31-8.36 (m, 2H) 9.08 (s, 1H); LCMS:
324 (M+H).
Example 9
##STR00021##
[0149] N-Isoquinolin-6-yl-2-m-tolylamino-acetamide: The title
compound was obtained as described in Step 2: .sup.1H NMR (400 MHz,
METHANOL-d.sub.4) .delta. ppm 2.23 (s, 3H) 3.95 (s, 2H) 6.43-6.57
(m, 3H) 7.02 (t, J=7.71 Hz, 1H) 7.67-7.77 (m, 2H) 8.02 (d, J=8.98
Hz, 1H) 8.30-8.37 (m, 2H) 9.08 (s, 1H); LCMS: 292 (M+H).
Example 10
##STR00022##
[0151]
3-[(Isoquinolin-6-ylcarbamoylmethyl)-amino]-N-pyridin-3-yl-benzamid-
e: The title compound was obtained as described in Step 2: .sup.1H
NMR (400 MHz, METHANOL-d.sub.4) .delta. ppm 4.08 (s, 2H) 6.89-6.94
(m, 1H) 7.24-7.33 (m, 3H) 7.42 (dd, J=8.40, 4.88 Hz, 1H) 7.71 (d,
J=5.86 Hz, 1H) 7.75 (dd, J=8.88, 2.05 Hz, 1H) 8.03 (d, J=8.98 Hz,
1H) 8.19-8.24 (m, 1H) 8.28 (dd, J=4.78, 1.46 Hz, 1H) 8.33 (d,
J=5.86 Hz, 1H) 8.36 (d, J=1.76 Hz, 1H) 8.85 (d, J=2.54 Hz, 1H) 9.09
(s, 1H); LCMS: 398 (M+H).
Example 11
##STR00023##
[0153] 3-[(Isoquinolin-6-ylcarbamoylmethyl)-amino]-benzamide: The
title compound was obtained as described in Step 2: .sup.1H NMR
(400 MHz, METHANOL-d.sub.4) .delta. ppm 4.04 (s, 2H) 6.84-6.88 (m,
1H) 7.15-7.20 (m, 2H) 7.24 (t, J=7.91 Hz, 1H) 7.71 (d, J=5.86 Hz,
1H) 7.74 (dd, J=8.98, 2.15 Hz, 1H) 8.02 (d, J=8.98 Hz, 1H) 8.36 (t,
J=2.44 Hz, 2H) 9.09 (s, 1H); LCMS: 321 (M+H).
Example 12
##STR00024##
[0155] 2-(3-Isopropoxy-phenylamino)-N-isoquinolin-6-yl-acetamide:
The title compound was obtained as described in Step 2: .sup.1H NMR
(400 MHz, METHANOL-d.sub.4) .delta. ppm 1.24 (d, J=6.05 Hz, 6H)
3.95 (s, 2H) 4.45-4.55 (m, 1H) 6.23 (t, J=2.25 Hz, 1H) 6.25-6.30
(m, 2H) 7.03 (t, J=8.10 Hz, 1H) 7.69-7.76 (m, 2H) 8.02 (d, J=8.79
Hz, 1H) 8.32-8.36 (m, 2H) 9.09 (s, 1H); LCMS: 336 (M+H).
Example 13
##STR00025##
[0157] N-Isoquinolin-6-yl-2-(3-sulfamoyl-phenylamino)-acetamide:
The title compound was obtained as described in Step 2: .sup.1H NMR
(400 MHz, METHANOL-d.sub.4) .delta. ppm 4.05 (s, 2H) 6.85-6.89 (m,
1H) 7.18-7.22 (m, 2H) 7.30 (t, J=8.20 Hz, 1H) 7.70 (d, J=5.86 Hz,
1H) 7.74 (dd, J=8.88, 2.05 Hz, 1H) 8.03 (d, J=8.98 Hz, 1H)
8.32-8.36 (m, 2H) 9.09 (s, 1H); LCMS: 357 (M+H).
Example 14
##STR00026##
[0159] 3-[(Isoquinolin-6-ylcarbamoylmethyl)-amino]-benzoic acid
methyl ester: The title compound was obtained as described in Step
2: .sup.1H NMR (400 MHz, METHANOL-d.sub.4) .delta. ppm 3.84 (s, 3H)
4.04 (s, 2H) 6.89-6.94 (m, 1H) 7.25 (t, J=7.81 Hz, 1H) 7.31-7.36
(m, 2H) 7.74-7.79 (m, 2H) 8.06 (d, J=8.98 Hz, 1H) 8.34 (d, J=6.05
Hz, 1H) 8.38 (d, J=1.95 Hz, 1H) 9.12 (s, 1H); LCMS: 336 (M+H).
Example 15
##STR00027##
[0161] 2-(3-Benzoyl-phenylamino)-N-isoquinolin-6-yl-acetamide: The
title compound was obtained as described in Step 2: .sup.1H NMR
(400 MHz, METHANOL-d.sub.4) .delta. ppm 4.02 (s, 2H) 6.95-7.00 (m,
1H) 7.02-7.04 (m, 1H) 7.05-7.09 (m, 1H) 7.30 (t, J=7.81 Hz, 1H)
7.35-7.41 (m, 2H) 7.48-7.55 (m, 1H) 7.69-7.76 (m, 4H) 8.04 (d,
J=8.98 Hz, 1H) 8.33-8.37 (m, 2H) 9.10 (s, 1H); LCMS: 382 (M+H).
Example 16
##STR00028##
[0163]
3-[(Isoquinolin-6-ylcarbamoylmethyl)-amino]-N-methyl-benzamide: The
title compound was obtained as described in Step 2: .sup.1H NMR
(400 MHz, METHANOL-d.sub.4) .delta. ppm 2.87 (s, 3H) 4.04 (s, 2H)
6.83 (dd, J=8.20, 2.54 Hz, 1H) 7.06-7.11 (m, 1H) 7.11-7.14 (m, 1H)
7.22 (t, J=7.81 Hz, 1H) 7.70 (d, J=5.86 Hz, 1H) 7.74 (dd, J=8.88,
2.05 Hz, 1H) 8.02 (d, J=8.98 Hz, 1H) 8.30-8.37 (m, 2H) 9.08 (s,
1H); LCMS: 335 (M+H).
Example 17
##STR00029##
[0165] 2-(3-Fluoro-phenylamino)-N-isoquinolin-6-yl-acetamide: The
title compound was obtained as described in Step 2: .sup.1H NMR
(400 MHz, METHANOL-d.sub.4) .delta. ppm 3.98 (s, 2H) 6.34-6.41 (m,
2H) 6.45-6.49 (m, 1H) 7.07-7.14 (m, 1H) 7.71 (d, J=5.86 Hz, 1H)
7.73 (dd, J=8.88, 2.05 Hz, 1H) 8.03 (d, J=8.79 Hz, 1H) 8.31-8.38
(m, 2H) 9.09 (s, 1H); LCMS: 296 (M+H).
Example 18
##STR00030##
[0167] 2-(3-Acetyl-phenylamino)-N-isoquinolin-6-yl-acetamide: The
title compound was obtained as described in Step 2: .sup.1H NMR
(400 MHz, METHANOL-d.sub.4) .delta. ppm 2.54 (s, 3H) 4.05 (s, 2H)
6.91-6.95 (m, 1H) 7.25-7.30 (m, 2H) 7.31-7.35 (m, 1H) 7.71 (d,
J=5.86 Hz, 1H) 7.74 (dd, J=8.88, 2.05 Hz, 1H) 8.03 (d, J=8.79 Hz,
1H) 8.31-8.37 (m, 2H) 9.09 (s, 1H); LCMS: 320 (M+H).
Reference Example One
[0168] The inhibition of G-protein-coupled receptor kinases
including hGRK-2 was determined for isoquinoline compounds as
disclosed herein using a biochemical assay. The inhibition of
GRK-3, GRK-5 and GRK-6 was also determined using the same
assay.
[0169] The protein kinase inhibition was determined using a
biochemical assay utilizing the light emission of a luciferase
reaction. The luciferase-based assay operates on the following
reaction principles:
##STR00031##
[0170] An inhibitor of GRK-2 will increase the amount of ATP in
solution as shown. Thus, an inhibitor of GRK-2 will drive the
luciferase reaction to the right, resulting in more light emitted.
The amount of light emitted is proportional to the inhibition
resulting from the GRK-2 inhibitor. The luciferase assay was also
used to test the inhibition properties of other kinases. The
results of the assay for GRK-2, GRK-3, GRK-5, and GRK-6 are
presented below in Table 1.
[0171] The test procedure was as follows:
Assay Buffer:
50 mM HEPES, pH 7.5
10 mM MgCl.sub.2
[0172] 100 .mu.M activated sodium orthovanadate
0.01% CHAPS
0.1% BSA
[0173] 1 mM DTT (added fresh daily)
10.times. Assay Buffer Stock:
500 mM HEPES, pH 7.5
100 mM MgCl.sub.2
[0174] 1 mM activated sodium orthovanadate
0.1% CHAPS
[0175] 1% BSA (leave out for 10.times. compound dilution
buffer)
Final Assay Conditions:
[0176] 50 .mu.M test compound 20 .mu.M casein
10 .mu.M ATP
[0177] 50 nM hGRK2
4.5% DMSO
[0178] 90-120 minute incubation
[0179] Stopped by addition of 30 .mu.l 3.times.-diluted Kinase-Glo
reagent containing 0.01% trypan blue. Counted on FUSION plate
reader.
Protocol
Compound Dilution and Transfer
[0180] Prepare sufficient buffer containing 40% DMSO to add 20
.mu.l/well to the number of plates being assayed. This buffer
should not contain BSA because it will precipitate with addition of
40% DMSO. (EXAMPLE: To make 3000 ml compound dilution buffer: 1200
ml DMSO, 180 ml 10.times. compound dilution buffer, 1615 ml
ultrapure water, 3 ml 1M DTT).
[0181] Using Multidrop, add 20 .mu.l of compound dilution buffer to
all wells of the 384-well daughter plate (add 1 .mu.l DMSO to
control wells). This will result in a daughter plate which contains
21 .mu.l of .about.500 .mu.M test compound.
[0182] Using the PlateTrak, transfer 5 .mu.l of the test compounds
to a 384-well, non-binding, white microtiter plate (Costar
XXXX).
GRK2/ATP Addition
[0183] Prepare sufficient volume of buffer (with BSA and 1 mM DTT)
containing 125 nM GRK2 and 25 .mu.M ATP. (EXAMPLE: To 219 ml buffer
add 550 .mu.l 10 mM ATP and 350 .mu.l 79 .mu.M GRK2).
[0184] Using Multidrop, add 20 .mu.l of GRK2/ATP mixture to all
wells of the microtiter plate.
Casein Addition
[0185] Prepare sufficient volume of buffer (with BSA and 1 mM DTT)
containing 40 .mu.M casein. (EXAMPLE: To 211 ml buffer add 8.8 ml 1
mM casein)
[0186] Using Multidrop, add 25 .mu.l to columns 1 through 23 of the
microtiter plate. Add 25 p. 1 of complete buffer to column 24
(blanks).
Incubation
[0187] Mix reaction gently by tapping (Multidrop addition of casein
does a decent job of mixing), stack plates and incubate at room
temperature for between 90 and 120 minutes. Assay progression can
be tracked in a separate plate if desired. Target 20-30% ATP
consumption. Try to avoid exceeding 40% consumption as kinetics
might become non-linear due to substrate (ATP) depletion.
Addition of Kinase-Glo Reagents
[0188] The Kinase-Glo reagent can be diluted 3-fold with no loss of
data quality in this assay. Additionally, since the library
contains many colored compounds which will quench the light emitted
from the well resulting in a false negative (kinase inhibitors
result in less ATP consumption thus more light emitted), the entire
reaction is subject to intentional quench to override this effect.
This intentional quench is accomplished by the addition of 0.01%
trypan blue to the Kinase-Glo reagents. (EXAMPLE: 100 ml 1.times.
Kinase-Glo reagents (prepared according to product insert), 200 ml
assay buffer, 7.5 ml 0.4% trypan blue.
[0189] Using Multidrop, add 30 .mu.l to all wells of the assay
plate.
[0190] Count on FUSION plate reader in luminescence mode.
[0191] The inhibition results for the foregoing Examples 1-18 are
for isoquinolines having the following general isoquinoline
structure:
##STR00032##
wherein R.sup.b is given separately for each example below in Table
1. The results are provided in terms of Ki (nM): 10-100 nM
Ki--++++
[0192] 100-1000 nM Ki--+++
[0193] 1000-10,000 nM Ki--++
[0194] >10,000 nM Ki--+.
TABLE-US-00001 TABLE 1 Max. Inhib. EX. R.sup.b GRK-2 (%) (GRK2)
GRK-3 GRK-5 GRK-6 1 OBn +++ 112 +++ +++ + 2 OMe ++++ 103 ++++ +++
+++ 3 CN ++ 91 ++ - + 4 CONHPh ++++ 99 ++++ +++ ++ 5 Cl +++ 102 +++
++ ++ 6 H +++ 112 +++ ++ ++ 7 OPh +++ 104 +++ ++ ++ 8 SMe ++++ 108
++++ ++ ++ 9 Me +++ 100 +++ ++ ++ 10 CONH-m- ++++ 106 ++++ +++ +++
Pyridine 11 CONH.sub.2 ++++ 102 ++++ ++ ++ 12 O-iPr ++++ 118 ++++
++ + 13 SO.sub.2NH.sub.2 ++ 115 ++ + + 14 COOMe +++ 104 +++ + + 15
COPh ++ 119 ++ + + 16 CONHMe ++++ 113 ++++ ++ ++ 17 F +++ 120 ++++
++ ++ 18 COMe +++ 116 +++ + +
Example 19
[0195] An isoquinoline having the following structure was prepared
as described above according to scheme 2.
##STR00033##
[0196] N-Isoquinolin-6-yl-2-(2-methoxy-phenylamino)-acetamide: The
title compound was obtained as described in Step 2: .sup.1H NMR
(400 MHz, METHANOL-d.sub.4) .delta. ppm 3.89 (s, 3H) 4.00 (s, 2H)
6.54 (dd, J=7.81, 1.56 Hz, 1H) 6.67-6.72 (m, J=7.61, 1.56 Hz, 1H)
6.78-6.83 (m, J=7.71, 1.46 Hz, 1H) 6.87 (dd, J=7.91, 1.27 Hz, 1H)
7.68-7.77 (m, 2H) 8.03 (d, J=8.98 Hz, 1H) 8.32-8.38 (m, 2H) 9.09
(s, 1H); LCMS: 308 (M+H).
[0197] This isoquinoline was also tested using the luciferase
biochemical assay. The maximum inhibition was 109% for GRK-2. The
results in K, (nM) using the scale above were as follows:
GRK-2--++
GRK-3--++
GRK-5--+
GRK-6--++
Example 20
[0198] An isoquinoline having the following structure was prepared
as described above according to scheme 2.
##STR00034##
[0199] N-Isoquinolin-6-yl-2-(4-methoxy-phenylamino)-acetamide: The
title compound was obtained as described in Step 2: .sup.1H NMR
(400 MHz, METHANOL-d.sub.4) .delta. ppm 3.69 (s, 3H) 3.91 (s, 2H)
6.61-6.69 (m, 2H) 6.74-6.82 (m, 2H) 7.67-7.79 (m, 2H) 8.03 (d,
J=8.79 Hz, 1H) 8.30-8.38 (m, 2H) 9.09 (s, 1H); LCMS: 308 (M+H).
[0200] This isoquinoline was also tested using the luciferase
biochemical assay. The maximum inhibition was 116% for GRK-2. The
results in K.sub.i (nM) using the scale above were as follows:
GRK-2--++
GRK-3--++
GRK-5--+
GRK-6--++
Example 21
[0201] An isoquinoline having the following structure was prepared
as described above according to scheme 2.
##STR00035##
[0202] N-Isoquinolin-6-yl-2-p-tolylamino-acetamide: The title
compound was obtained as described in Step 2: .sup.1H NMR (400 MHz,
METHANOL-d.sub.4) .delta. ppm 2.19 (s, 3H) 3.93 (s, 2H) 6.56-6.63
(m, 2H) 6.97 (d, J=8.00 Hz, 2H) 7.66-7.76 (m, 2H) 8.01 (d, J=8.79
Hz, 1H) 8.28-8.37 (m, 2H) 9.08 (s, 1H); LCMS: 292 (M+H).
[0203] This isoquinoline was also tested using the luciferase
biochemical assay. The maximum inhibition was 116% for GRK-2. The
results in K.sub.i (nM) using the scale above were as follows:
GRK-2--++
GRK-3--++
GRK-5--+
GRK-6--++.
Example 22
[0204] An isoquinoline having the following structure was prepared
as described above according to scheme 2.
##STR00036##
[0205] 2-(3,5-Dimethoxy-phenylamino)-N-isoquinolin-6-yl-acetamide:
The title compound was obtained as described in Step 2: NMR (400
MHz, METHANOL-d.sub.4) .delta. ppm 3.70 (s, 6H) 3.94 (s, 2H)
5.82-5.94 (m, 3H) 7.67-7.79 (m, 2H) 8.03 (d, J=8.79 Hz, 1H)
8.28-8.40 (m, 2H) 9.09 (s, 1H); LCMS: 338 (M+H).
[0206] This isoquinoline was also tested using the luciferase
biochemical assay. The maximum inhibition was 124% for GRK-2. The
results in K.sub.i (nM) using the scale above were as follows:
GRK-2--++
GRK-3--++
GRK-5--++
GRK-6--++.
Example 23
[0207] An isoquinoline having the following structure was prepared
as described above according to scheme 2.
##STR00037##
[0208] N-Isoquinolin-6-yl-2-(3-methoxy-benzylamino)-acetamide: The
title compound was obtained as described in Step 2: .sup.1H NMR
(400 MHz, METHANOL-d.sub.4) .delta. ppm 3.45 (s, 2H) 3.77 (s, 3H)
3.81 (s, 2H) 6.76-6.83 (m, 1H) 6.91-7.00 (m, 2H) 7.19-7.27 (m, 1H)
7.68-7.76 (m, 2H) 8.04 (d, J=8.79 Hz, 1H) 8.32-8.37 (m, 2H) 9.10
(s, 1H); LCMS: 322 (M+H).
[0209] This isoquinoline was also tested using the luciferase
biochemical assay. The maximum inhibition was 111% for GRK-2. The
results in K.sub.i (nM) using the scale above were as follows:
GRK-2--++
GRK-3--++
GRK-5--+
GRK-6--+.
Example 24
[0210] An isoquinoline having the following structure was prepared
as described above according to scheme 2.
##STR00038##
[0211] 2,3-Dihydro-1H-indole-2-carboxylic
acid-isoquinolin-6-yl-amide: To a solution of 6-aminoisoquinoline
(25 mg, 0.17 mmol) in DMF (1.0 mL) was added indoline-2-carboxylic
acid (30 mg, 0.17 mmol), HATU (70 mg, 0.19 mmol),
diisopropylethylamine (35 .mu.L, 0.19 mmol) and stirred overnight
at 40.degree. C. The reaction mixture was concentrated and purified
by prep-HPLC to afford the titled compound (3.0 mg): .sup.1H NMR
(400 MHz, METHANOL-d.sub.4) 8 ppm 3.18 (dd, J=16.11, 8.30 Hz, 1H)
3.56 (dd, J=16.20, 10.54 Hz, 1H) 4.52 (dd, J=10.54, 8.40 Hz, 1H)
6.70-6.81 (m, 2H) 6.99-7.10 (m, 3H) 7.73 (d, J=6.05 Hz, 1H) 7.81
(dd, J=8.88, 2.05 Hz, 1H) 8.05 (d, J=8.98 Hz, 1H) 8.35 (d, J=5.86
Hz, 1H) 8.40 (d, J=1.95 Hz, 1H) 9.11 (s, 1H); LCMS: 290 (M+H).
[0212] This isoquinoline was also tested using the luciferase
biochemical assay. The maximum inhibition was 110% for GRK-2. The
results in K.sub.i (nM) using the scale above were as follows:
GRK-2--++
GRK-3--++
GRK-5--+
GRK-6--+.
Example 25
[0213] The isoquinolines of Examples 2-4 were also screened in
cellular assays for GRK-2 inhibitory effect. The results are shown
in FIGS. 1-9. The figures show the effect of the three different
isoquinolines in the translocation of several receptors. The
Transfluor assay (Assay and Drug Development Technologies, Volume
1, Number 1-1, pages 21-30, (2002); U.S. Pat. No. 5,891,646, and
U.S. Pat. No. 6,110,693, each incorporated herein by reference in
its entirety) was used to measure the degree of translocation in
U2OS cells that over express the receptor and arrestin.
[0214] FIGS. 1-3 show the effect of the isoquinoline described in
Example 2 (GRK-2 Ki=0.022 micromolar), in the isoproterenol-induced
translocation of arrestin-GFP to the Beta 2 Adrenergic Receptor
(B2wt). FIG. 1 shows dose response curves for the effect of
isoproterenol (a Beta 2 Adrenergic receptor agonist) against
F-grains (a measure of the degree of arrestin-GFP translocation to
the receptor) for increasing concentrations of the isoquinoline
(see curves). For any given concentration of isoproterenol, as the
concentration of isoquinoline increases, there is a stepwise
reduction in translocation (decrease in F-grains). By preventing
GRK-2 mediated phosphorylation of the receptor, the isoquinoline
prevents binding of arrestin-GFP to the receptor. FIG. 2 shows the
same effect on the Beta 1 Adrenergic receptor (B1wt), and FIG. 2 is
the effect on the mu opioid receptor. FIGS. 4-6 and FIGS. 7-9 show
the effect of two other isoquinolines, the isoquinoline from
Example 3 (GRK-2 Ki=1.8 micromolar) and the isoquinoline of Example
4, (GRK-2 Ki=0.037 micromolar), respectively, in the same three
receptors as tested for the isoquinoline of Example 2.
[0215] The isoquinoline of Example 2 and the isoquinoline of
Example 4, which are very good inhibitors of GRK-2 show modest
inhibition of arrestin-GFP translocation to the B2WT, B1WT, but
strong inhibition to the mu opioid. The isoquinoline of Example 3,
however, which is a weaker inhibitor of GRK-2, shows much less
inhibition of translocation in all three receptors. Finally,
increased concentrations of either the isoquinoline of Example 2 or
Example 4 showed increased accumulation of cAMP in HEK-293 cells
(Beta 2 Adrenergic receptor overexpressed) in the presence of a
fixed concentration of isoproterenol. This is consistent with the
inhibition of GRK-2 resulting in less translocation of
arrestin-GFP, less desensitization, and consequently more signaling
by the B2AR. With more receptors available now on the surface of
the cell, more cAMP is being generated in the presence of
Isoproterenol. The isoquinoline of Example 3, which is a weak
inhibitor of GRK-2 and shows much less inhibition of translocation
also has less effect on the amount of cAMP accumulated in the
cell.
[0216] In FIG. 1, the IC50 of the .beta.2 arrestin was 8 .mu.M. In
FIG. 3, the IC50 for the mu-opioid receptor was less than 1 .mu.M.
In FIG. 4, the IC50 of the 132 arrestin was greater than 100 .mu.M.
In FIG. 5, the IC50 for the 131 arrestin was greater than 100
.mu.M. In FIG. 6, the IC50 for the mu-opioid receptor was greater
than 100 .mu.M. In FIG. 7, the IC50 of the 132 arrestin was 4
.mu.M. In FIG. 8, the IC50 for the .beta.1 arrestin was greater
than 100 .mu.M. In FIG. 9, the IC50 for the mu-opioid receptor was
less than 1 .mu.M.
[0217] The isoquinolines may further be screened for effect on GPCR
desensitization by use of the methods described in U.S. Patent
Application No. 2004/0091946, published May 13, 2004, or U.S.
Patent Application No. 2005/0032125, published Feb. 10, 2005, both
incorporated herein by reference in their entirety.
Example 26
##STR00039##
[0219] 2-(4-Benzoyl-phenylamino)-N-isoquinolin-6-yl-acetamide: The
title compound could be obtained as described in Step 2 above.
Reference Example Two
Cell-Based Porcine Trabecular Meshwork (PTM) Assay
[0220] The anterior section of porcine eyes was harvested within 4
hours post-mortem. The iris and ciliary body were removed and
trabecular meshwork cells were harvested by blunt dissection.
Finely minced trabecular meshwork tissue was plated into
collagen-coated 6-well plates in Medium-199 containing 20% fetal
bovine serum (FBS). After two passages at confluence, cells were
transferred to low-glucose DMEM containing 10% FBS. Cells were used
between passage 3 and passage 8.
[0221] Cells were plated into fibronectin-coated, glass multiwell
plates the day before compound testing under standard culture
conditions. Compounds were added to cells in the presence of 1%
FBS-containing DMEM and 1% DMSO. When compounds were incubated with
the cells for the duration determined to be optimal, the media and
compound is removed and cells fixed for 20 minutes in 3%
methanol-free paraformaldehyde. Cells were rinsed twice with
phosphate buffered saline (PBS) and cells are permeabilized with
0.5% Triton X-100 for two minutes. Following an additional two
washes with PBS, F-actin was stained with Alexa-fluor 488-labelled
phalloidin and nuclei are stained with DAPI.
[0222] Data was reduced to the mean straight actin-fiber length and
normalized to DMSO-treated control cells (100%) and 50 .mu.M
Y-27632 (0%). Y-27632 is a rho-kinase inhibitor known to result in
the depolymerization of F-actin in these cells.
Example 27
[0223] The cellular assay described in Reference Example Two was
used to test the foregoing Examples 1-18, the results of which are
presented below. For reference, these are isoquinolines having the
following general isoquinoline structure:
##STR00040##
wherein R.sup.b is given separately for each example below in Table
2. The results are provided in terms activity at 50 .mu.M as
compared to control More active than control--+++ As active as
control ++ Less active than control +
Inactive -
TABLE-US-00002 [0224] TABLE 2 Example R.sup.b PTM Cell Assay 1
OCH2Ph + 2 OMe +++ 3 CN +++ 4 CONHPh +++ 5 Cl ++ 6 H ++ 7 OPh +++ 8
SMe +++ 10 CONH-m-Pyridine +++ 14 COOMe +++ 15 COPh ++
Example 28
[0225] An isoquinoline having the following structure was prepared
as described above according to scheme 2 as set forth in Example
20.
##STR00041##
[0226] This isoquinoline was also tested using the PTM Cell Assay
as described in reference Reference Example Two. The results using
the scale above were as follows:
[0227] PTM Cell Assay +
Example 29
[0228] An isoquinoline having the following structure was prepared
as described above according to scheme 2 as set forth in Example
21.
##STR00042##
This isoquinoline was also tested using the PTM Cell Assay as
described in Reference Example Two. The results using the scale
above were as follows:
[0229] PTM Cell Assay ++
Example 30
[0230] An isoquinoline having the following structure was prepared
as described above according to scheme 2 as set forth in Example
22.
##STR00043##
This isoquinoline was also tested using the PTM Cell Assay as
described in Reference Example Two. The results using the scale
above were as follows:
[0231] PTM Cell Assay -
Example 31
[0232] An isoquinoline having the following structure was prepared
as described above according to scheme 2 as set forth in Example
23.
##STR00044##
This isoquinoline was also tested using the PTM Cell Assay as
described in reference Example Two. The results using the scale
above were as follows:
[0233] PTM Cell Assay ++
Reference Example Three
Pharmacological Activity for Glaucoma Assay
[0234] Pharmacological activity for glaucoma can be demonstrated
using assays designed to test the ability of the subject compounds
to decrease intraocular pressure. Examples of such assays are
described in the following reference, incorporated herein: C.
Liljebris, G. Selen, B. Resul, J. Sternschantz, and U. Hacksell,
"Derivatives of 17-Phenyl-18,19,20-trinorprostaglandin
F.sub.2.alpha. Isopropyl Ester: Potential Antiglaucoma Agents",
Journal of Medicinal Chemistry, Vol. 38 (2) 1995, pp. 289-304.
Example 32
[0235] Topical pharmaceutical compositions for lowering intraocular
pressure are prepared by conventional methods and formulated as
follows:
TABLE-US-00003 Ingredient Amount (wt %) Isoquinoline Derivative
0.50 Dextran 70 0.1 Hydroxypropyl methylcellulose 0.3 Sodium
Chloride 0.77 Potassium chloride 0.12 Disodium EDTA 0.05
Benzalkonium chloride 0.01 HCl and/or NaOH pH 7.0-7.2 Purified
water q.s. to 100%
[0236] A compound according to this invention is used as the
isoquinoline derivative. When the composition is topically
administered to the eyes once daily, the above composition
decreases intraocular pressure in a patient suffering from
glaucoma.
Example 33
[0237] Example 32 is repeated using
N-Isoquinolin-6-yl-2-p-tolylamino-acetamide according to this
invention. When administered as a drop 4 times per day, the above
composition substantially decreases intraocular pressure and serves
as a neuroprotective agent.
Example 34
[0238] Example 32 is repeated using
2-(3-Benzoyl-phenylamino)-N-isoquinolin-6-yl-acetamide according to
this invention. When administered as a drop twice per day, the
above composition substantially decreases intraocular pressure.
Example 35
[0239] Example 32 is repeated using
3-[(Isoquinolin-6-ylcarbamoylmethyl)-amino]-N-pyridin-3-yl-benzamide
according to this invention. When administered as a drop twice per
day, the above composition substantially decreases allergic
symptoms and relieves dry eye syndrome.
Example 36
[0240] Example 32 is repeated using a
4-[(Isoquinolin-6-ylcarbamoylmethyl)-amino]-N-pyridin-4-yl-benzamide
according to this invention. When administered as a drop as needed,
the above composition substantially decreases hyperemia, redness
and ocular irritation.
Example 37
[0241] Example 32 is repeated using
N-(isoquinolin-6-yl)-2-(4-methoxyphenylamino)acetamide according to
this invention. When administered as a drop 4 times per day, the
above composition substantially decreases intraocular pressure and
serves as a neuroprotective agent.
Example 38
[0242] Example 32 is repeated using
N-(isoquinolin-6-yl)-2-(4-(methylthio)phenylamino)acetamide
according to this invention. When administered as a drop twice per
day, the above composition substantially decreases intraocular
pressure.
Example 39
[0243] Example 32 is repeated using phenyl
3-(2-(isoquinolin-6-ylamino)-2-oxoethylamino)benzoate according to
this invention. When administered as a drop twice per day, the
above composition substantially decreases allergic symptoms and
relieves dry eye syndrome.
Example 40
[0244] Example 32 is repeated using phenyl
4-(2-(isoquinolin-6-ylamino)-2-oxoethylamino)benzoate according to
this invention. When administered as a drop as needed, the above
composition substantially decreases allergic symptoms
Example 41
[0245] Example 32 is repeated using
N-(isoquinolin-6-yl-(3-(methylthio)phenylamino) acetamide according
to this invention. When administered as a drop as needed, the above
composition substantially decreases hyperemia, redness and ocular
irritation.
Example 42
[0246] Example 32 is repeated using
N-(2-fluorophenyl)-4-(2-(isoquinolin-6-ylamino)-2-oxoethylamino)benzamide
according to this invention. When administered as a drop twice a
day or as needed, the above composition substantially decreases
intraocular pressure.
Example 43
[0247] Example 32 is repeated using
N-(2-fluorophenyl)-2-(2-(isoquinolin-6-ylamino)-2-oxoethylamino)benzamide
according to this invention. When administered as a drop twice a
day or as needed, the above composition substantially decreases
intraocular pressure.
Example 44
[0248] Example 32 is repeated using
N-(isoquinolin-6-yl)-2-(3-sulfamoylphenylamino)acetamide according
to this invention. When administered as a drop twice a day or as
needed, the above composition substantially decreases intraocular
pressure.
Example 45
[0249] Example 32 is repeated using
N-(isoquinolin-6-yl)-2-(4-sulfamoylphenylamino)acetamide according
to this invention. When administered as a drop twice a day or as
needed, the above composition substantially decreases intraocular
pressure.
Example 46
[0250] Example 32 is repeated using
N-(isoquinolin-6-yl)-2-(4-(N-methylsulfamoyl)phenylamino)acetamide
according to this invention. When administered as a drop twice a
day or as needed, the above composition substantially decreases
intraocular pressure.
[0251] While the invention has been described in detail and with
reference to specific embodiments thereof, it will be apparent to
one skilled in the art that various changes and modifications can
be made without departing from the spirit and scope of the
invention.
* * * * *